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Abstract
Over the last several years, evidence has accumulated that the GABAA receptor is compro-
mised in animal models for fragile X syndrome (FXS), a common hereditary form of intellec-
tual disability. In mouse and fly models, agonists of the GABAA receptor were able to rescue
specific consequences of the fragile X mutation. Here, we imaged and quantified GABAA
receptors in vivo in brain of fragile X patients using Positron Emission Topography (PET)
and [11C]flumazenil, a known high-affinity and specific ligand for the benzodiazepine site of
GABAA receptors. We measured regional GABAA receptor availability in 10 fragile X
patients and 10 control subjects. We found a significant reduction of on average 10% in
GABAA receptor binding potential throughout the brain in fragile X patients. In the thalamus,
the brain region showing the largest difference, the GABAA receptor availability was even
reduced with 17%. This is one of the first reports of a PET study of human fragile X brain
and directly demonstrates that the GABAA receptor availability is reduced in fragile X
patients. The study reinforces previous hypotheses that the GABAA receptor is a potential
target for rational pharmacological treatment of fragile X syndrome.
Introduction
Fragile X syndrome patients show mild to severe cognitive impairment and have a distinct
physical appearance [1]. Many behavioral problems, such as hyperactivity, aggression, social
anxiety, impaired sensorimotory gating and autistic-like features, are associated with the syn-
drome [2]. In addition, an increased risk of epileptic seizures is reported [3]. Fragile X
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syndrome is caused by mutations in the FMR1-gene, which is characterized by an expansion of
a CGG triplet in the 5’UTR. Normal individuals have 6–44 CGG repeats, while carriers of gray
zone or premutation alleles have 45–54 and 55–200 repeats, respectively. Gray zone and pre-
mutation alleles inherit unstable and the latter category has a strong tendency to expand to the
full mutation range (>200 repeats) upon maternal transmission. FMR1 silencing is the conse-
quence of rather complex epigenetic modifications. The mRNA containing the elongated CGG
repeat has been demonstrated to bind to its own promotor during cellular differentiation,
resulting in transcriptional silencing of the gene and loss of the protein FMRP in carriers of the
methylated full mutation [4]. FMRP is an RNA-binding protein involved in RNA transport
from the nucleus to the dendrites where it is known to regulate translation of proteins impor-
tant for synaptic development and plasticity (reviewed in [5, 6]).
Previously, we and others have shown a decreased mRNA expression of specific GABAA
receptor subunits and other components of the GABAergic system in brain tissue from mouse
and fly models for fragile X syndrome (reviewed in [7]). GABAA receptors are the major inhib-
itory receptors in the mammalian brain implicated in anxiety, depression, epilepsy, insomnia,
and learning and memory [8], processes also disturbed in FXS. Ionotropic GABAA receptors
are heteropentameric assemblies of 5 subunits, which are chosen out of 19 identified subunits
in mammals: α1–6, β1–3, γ1–3, δ, ε, ρ1–3, θ and π [9] and which are unlinked to the FXS causative
FMR1 gene. Treatment with agonists of the GABAA receptor has been shown effective in ani-
mal models [10–14]. Before treatment on patients can be initiated, it is important to know
whether the abnormalities observed in animal models are also detectable and quantifiable in
patients. Studies on isolated tissues are not feasible on fragile X patients due to a scarcity of
post-mortem materials. To determine whether the GABAergic system is affected in fragile X
patients, we quantified the GABAA receptor distribution in vivo using positron emission
tomography (PET). PET is a functional imaging technology that provides a non-invasive in
vivo assessment and quantification of receptor binding through administration of selective
radio ligands that target specific receptors [15, 16]. In this study, we used [11C]flumazenil, a
known high-affinity and specific radio ligand of the GABAA receptor, to visualize the receptor
occupancy in human FXS brain. Parametric binding potential images of 10 fully characterized
male fragile X patients were compared with those of 10 healthy volunteers.
Materials and Methods
Human volunteers and study design
This study was approved by the medical ethics committee of the University of Antwerp and the
KULeuven. Written informed consent was obtained from each fragile X patient, or his legal
guardian, and from each healthy control before research participation. The study was conducted
in accordance with statutes and regulations regarding the protection of the right and welfare of
human subjects’ participation in biomedical research (World Declaration of Helsinki). Ten
healthy male subjects (mean age 35.9, range: 24–51 years) and 10 male fragile X patients (mean
age 38.1, range: 23–53 years) were enrolled (S1 Table). The absence/presence of the fragile X
mutation was confirmed in all participants, using a CGG-repeat PCR and Southern Blotting on
DNA isolated from blood. All subjects fulfilled strict inclusion and exclusion criteria. Inclusion
criteria were: male subjects, in good health (as confirmed by physical examination and routine
laboratory analysis), and within the age range of 16–55 years of age. Exclusion criteria were:
drug/medication abuse, hypersensitivity to medication or flumazenil or benzodiazepines or lido-
cain, any history of neurological disorders or any other major internal disorder, history of psy-
chiatric disorders. Consumption of any medication or over the counter drug between 2 weeks
before or after the study was not allowed. In this regard, only one patient (patient 6) took
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medication, a spasmolyticum (1 Kemadrin 5mg/day), a benzodiazepine (3/4 Rivotril 2mg/day)
and antipsychotica (3 Dipiperon 40mg/day and 1 Largactil 50mg/day) at the time of recruit-
ment. However, medication intake was stopped without major behavioral implications under
supervision of a medical doctor. Current heavy smokers (defined as more than 5 cigarettes/day),
or heavy smokers who quit less than 3 months before the study, were excluded and consumption
of no more than 3 cups caffeine-containing beverages/day (coffee, tea, coke) was allowed. Alco-
hol usage was prohibited between 2 days before and after study. For radioprotection purposes,
previous participants in studies using ionizing radiation during previous 12 months were
excluded. Controls were recruited along the same criteria. The characteristics of the subject pop-
ulation, including the results of the psychological testing are provided in S1 Table.
DNA isolation and fragile X screening
DNA isolation from blood was performed using an automated liquid handling systemMultip-
robe II plus ex (Perkin Elmer, Waltham, MA, USA) and the chemagic magnetic separation
module (Chemagen, Baesweiler, Germany) based on the magnetic beads principle. The length
of the CGG-repeat in the 5’UTR of the FMR1 gene was measured using a touchdown PCR
with the following primers: FRAXA-F: CGGAGGCGCCGCTGCCAGG and FRAXA-R:
TGCGGGCGCTCGAGGCCCAG. PCR products were analysed using capillary gel electrophoresis
(ABI3130XL, ABI, Foster city, CA, USA). In case of a male fragile X full-mutation the CGG-
expansion is>200 repeats and the PCR will not be able to amplify the repeat. Consequently,
large CGG-repeats and methylation status at the level of the FMR1 gene were investigated using
Southern Blot withHindIII/EagI (New England Biolabs, Ipswich, MA, USA) as described [17].
Neurological assessment
All fragile X patients were subjected to a standard neurological examination, including higher
mental functions, cranial nerves, meningeal stimulation signs, locomotion, sensibility, reflexes,
coordination and motion by a board certified neurologist. Fragile X patients as well as healthy
controls were subjected to an EEG.
Neuropsychological assessment
All healthy controls and fragile X patients were subjected to a neuropsychological examination,
the Wechsler Adult Intelligence Scale (WAIS III), by a certified psychologist (S1 Table). Corre-
lations with GABAA receptor binding potential values (volume of interest-based comparisons)
were made with the scaled values for full scale IQ (TIQ), verbal IQ (VIQ) and performance IQ
(PIQ) and with the scaled values of the four index scores (verbal comprehension (VCI), percep-
tual organization (POI), working memory (WMI) and processing speed (PSI)). To avoid floor
effects, the scaled IQ scores are age-corrected, showing a correct measure of the capability of
the patients.
Radio ligand preparation
PET imaging was performed using the tracer [11C]flumazenil, a ligand that binds to α subunits
of the GABAA receptor. The routine synthesis of [
11C]flumazenil was performed as described
previously [18].
Anaesthesia
Fragile X patients were anesthetized before PET scanning using dexmedetomidine (Precedex,
Hospira, Inc., USA). Sedation was initiated with a bolus dose of 0.5–1 μg/kg and maintained by
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a continuous infusion of dexmedetomidine (0.25 μg/kg/h). Two healthy controls underwent
scanning with and without dexmedetomidine to evaluate in vivo differences on the GABAA
binding potential of flumazenil.
PET imaging
For each subject, a bolus of on average 265.4 MBq (SD 45.8) of [11C]flumazenil was injected
through an intravenous catheter. Simultaneously, a dynamic emission scan was started in
three-dimensional mode, consisting of 21 frames with progressive frame duration (4x15s,
2x30s, 3x1min, 2x2.5 min, 10x5min). Total scan duration was 60 min. PET acquisitions were
performed using a HiRez Biograph 16 PET-CT camera (Siemens, Erlangen, Germany). Images
were reconstructed with a standard three-dimensional filtered-back protection (3DRP) algo-
rithm, including scattered and measured attenuation correction. The resulting transverse and
axial spatial resolution is approximately 5mm. Dynamic data were motion corrected and spa-
tially normalized to MNI (Montreal Neurological Institute) space (PMOD 2.95, Zurich, Swit-
zerland). A voxel-based reference tissue model approach was used (Ichise model, MRTM2,
PMOD v2.9, PMOD Inc, Zurich) to calculate binding potential (BPND) [19] parametric maps
with the pons as reference region [20]. On the spatially normalized maps, a predefined VOI
analysis was performed. The same VOI definition, based on Brodmann areas, was used as in
previous studies, where larger cortical VOIs were defined in order to reduce type I errors [21].
The following VOIs were measured: frontal, temporal, mesial temporal, parietal, occipital, cen-
tral and cingulate cortical brain regions and the thalamus. To account for slight differences in
subcortical VOI placement due to spatial normalisation, the subcortical VOIs were manually
adjusted to the activity images for those areas by means of shifting and scaling when needed.
To exclude that demographic variables and PET injection parameters are the cause of the dif-
ferences in BP values, correlations between the group BP values and age, weight, injection
activity and specific activity of the flumazenil tracer were made. No correlations were found.
Statistical analysis
Statistical calculations were performed using SPSS. Independent samples t-test was used to
compare BPND values between groups. BPND values were also expressed in z-scores to indicate
the number of standard deviations by which the measured BP for any given subject differed
from the mean. Z-scores were calculated by subtracting the mean population BP for the total
grey matter (BPND group_AVG) from the observed total grey matter BP per subject and divid-
ing by the standard deviation of the population BP (BPND group_SD). Pearson correlations
were made to study the relationship between BPND values and IQ values. Correlative results
were not corrected for multiple testing but were reported as exploratory. Uncorrected p-values
are given for descriptive reasons only.
Results
All participants, fragile X patients and healthy volunteers, were screened for the fragile X full
mutation. All patients showed a fully methylated full mutation in blood, and mosaicism was
not detected on Southern blot. All volunteers showed a single band in the unaffected size range
for FXS, indicating absence of fragile X syndrome or any of the premutation related disorders.
All patients and healthy volunteers underwent standard neurological examination, and no spe-
cific clinical neurological abnormalities were detected. All study participants were subjected to
electroencephalography (EEG). No gross abnormalities or epileptic discharges were observed.
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PET imaging
[11C]flumazenil PET scans were performed on 10 fully characterized male FXS patients (Age
35.9 ± 3.7) and 10 healthy controls (Age 38 ± 3.7, for inclusion- exclusion criteria, see Materials
and Methods section). Given the impact of the experimental procedure and the high incidence
of anxiety amongst FXS subjects, patients were lightly sedated with dexmedetomidine. Dexme-
detomidine has sedative, analgesic, sympatholytic, and anxiolytic properties and is relatively
unique in its ability to provide sedation without causing respiratory depression. It was selected
as, in contrast to most anaesthetics exerting their action through GABAA receptors, the mecha-
nism of action of dexmedetomidine is agonism of α2-adrenergic receptors. By scanning two
healthy volunteers twice, once with and once without dexmedetomidine sedation we confirmed
this anaesthetic does not interfere with the outcome of our study. The non-displaceable binding
potential (BPND; the free plus non-specifically bound concentration in brain), which reflects
the availability of GABAA receptors, showed a significant mean decrease of 10% (BPND
group_AVG = 3.31, BPND HV = 3.48, BPND FXP = 3.14; p = 0.036; with z-scores ranging from
-0.36 to 1.41 for the controls and -1.83 to 1.20 for the patients) in total grey matter binding of
flumazenil in FXS patients when compared to the controls (Figs 1 and 2; S1 Fig). The decrease
ranged from 6–17% in different regions of the brain but was fairly homogeneous. Regionally,
the decrease in BPND was significant in the parietal (BPND parietal_AVG = 3.45, BPND
HV = 3.64, BPND FXP = 3.26; p = 0.038), central (BPND central_AVG = 3.19, BPND HV = 3.36,
BPND FXP = 3.02; p = 0.048) and cingulate (BPND cingulate_AVG = 3.87, BPND HV = 4.09,
BPND FXP = 3.65; p = 0.016) cortical regions, and in the thalamus (BPND thalamus_AVG = 1.84,
BPND HV = 2.02, BPND FXP = 1.67; p = 0.001).
Five patients showed BPND values within the range of the controls and 5 showed ranges
below these values (S2 Fig). It is striking that the intergroup variance in BPND values within the
patient group is significantly larger than the variance within the control group (Levene’s test,
Fig 1. Transversal, sagittal and coronal slices of GABAA receptor PET images expressed in [11C]
flumazenil binding potential (BPFMZ) values, averaged for the 10 healthy controls (HV, upper panel)
and the 10 fragile X patients (FXP, lower panel). BPND values are indicated by the color bar.
doi:10.1371/journal.pone.0131486.g001
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p<0.05, data not shown). This observation indicates that factors other than the fragile X muta-
tion may potentially influence flumazenil binding to the receptor, as previously suggested by
FXS modifier genes [22]. Alternatively, the high intergroup variance may indicate mosaicism
for the presence of a full mutation and a permutation in the brain. Although we excluded
mosaicism in the blood of our patients, mosaicism in other tissues can never be excluded.
Cognitive testing
The cognitive ability of patients and healthy controls was examined with the WAIS III test (S1
Table). The full scale IQ score (TIQ) of the FXS patients was 50 ± 2 (mean ± S.E.M.). There
was no significant difference between mean verbal IQ (VIQ), which measures the verbal, crys-
tallized abilities, and mean performance IQ (PIQ), which measures the nonverbal, fluid abili-
ties, with a score of 48 ± 2 and 49 ± 3, respectively. The TIQ can be subdivided into four index
scores: verbal comprehension (VCI), perceptual organization (POI), working memory (WMI),
and processing speed (PSI). These four mean index scores were obtained for 8 patients and
were 55 ± 3 (VCI), 55 ± 3 (POI), 52 ± 1 (WMI) and 51 ± 1 (PSI), respectively. These scores
agree with earlier observations and confirm that there were no specific weaknesses or strengths
in any of the index domains. It is remarkable that the patient showing the highest total BPND
value also has the highest IQ (69). Therefore, we correlated the [11C] flumazenil BPND values
with the scaled IQ scores and index scores in patients and control subjects and found a strong
correlation between the BPND of thalamus and all IQ sub scores in patients (TIQ: r = 0.844;
VIQ: r = 0.866; PIQ: r = 0.804) and index scores (VCI: r = 0.806,; POI: r = 0.845; WMI: 0.855;
PSI: r = 0.765) (Table 1 and Fig 3). No relevant correlations were found between IQ scores and
BPND values in the healthy controls. It is important to note that this pilot study is not sufficient
to draw significant statistical conclusions concerning a possible correlation between GABAA
receptor availability and IQ scores and further expansion of our patient cohort is necessary.
Fig 2. Bar chart of GABAA receptor availability expressed in mean binding potential (BP) values of
[11C]flumazenil.GABAA receptor availability is significantly decreased in the fragile X patient group (FXP)
compared to the control group (healthy volunteers, HV) for the regions indicated with * (*: p<0.05, **:
p<0.01). Group represents the composite VOI resulting from the weighted sum of all VOIs in the study, and
includes total grey matter. Error bars indicate SEM (n = 10/group). VOIs represented include all cortical
regions and the thalamus. Cerebellum and striatum are not included.
doi:10.1371/journal.pone.0131486.g002
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Discussion
PET may be a key technology in identifying the physiological consequences of gene mutations
associated with intellectual disabilities [23]. The utility of PET in elucidating the functional
consequences of specific genetic abnormalities was previously reported in the Angelman and
Prader-Willi syndromes. Both diseases result from a maternal and paternal deletion, respec-
tively, of an imprinted region on chromosome 15q11-q13, encoding the GABAA receptor sub-
unit genes β3, α5 and γ3 [24, 25]. Six Prader-Willi patients showed a 14% global decrease in
[11C]flumazenil binding [26], while a significantly decreased GABAA receptor occupancy was
observed in specific brain regions of Angelman patients [27]. These observations demonstrate
that a deletion of specific subunits may result in a measurable reduction of the amount of
GABAA receptors in the brain. Even though we have no information on the expression alter-
ations of individual subunits of the GABAA receptor in FXS patients, the data in these deletion
patients suggest that a reduction in expression of of 8 GABAA receptor subunits on the mRNA
level, as observed in FXS animal models, can have a significant impact on the amount of recep-
tor protein in the brain.
To assess the functional consequences of a reduced amount of GABAA receptor mRNA and
protein observed in fragile X animal models (reviewed in [7]) binding levels of the radioligand
[11C] flumazenil to the GABAA receptor in the brain of fragile X patients were investigated
using PET. We observed a significant decrease of 6-17% in brain GABAA receptor availability
in the patient cohort. This decrease may even be an underestimation of the effect in the total
fragile X patient population. First of all, an important difference between fragile X patients and
controls is that mild sedation with a α2-adrenergic agonist, dexmedetomidine, was only used in
the patient group. To estimate the potential bias of dexmedetomidine anaesthesia on the [11C]
flumazenil BPND in patients in vivo, two healthy controls were scanned twice on two consecu-
tive days, the first day without and the second day with dexmedetomidine sedation. We
observed a mild increase (4.9–6.0%) in grey matter BPND after sedation, suggesting a negative
confound on the observed effect between patients and controls. Studies in animal models may
further answer this question. Secondly, only mildly affected fragile X patients could be enrolled
in this study because of the impact of the experimental protocol on the patient. This selection
may have created a bias and GABAA receptor occupancy values may be even more decreased,
had we been able to measure a more severely affected group of patients. Lastly, flumazenil is an
antagonist that binds to the benzodiazepine binding site of the GABAA receptor and as a
Table 1. Volume of interest-based correlation between FMZ BP and IQ and index scores for the healthy volunteers and fragile X patients. Abbrevia-
tions: TIQ: total IQ score, VIQ: verbal IQ, PIQ: performance IQ, VCI: verbal comprehension index, POI: perceptual organization index, WMI: working memory
index, PSI: processing speed index.
Healthy Volunteers (n = 10) Fragile X Patients (n = 8)
TIQ VIQ PIQ VCI POI WMI PSI TIQ VIQ PIQ VCI POI WMI PSI
Group -.198 -.124 -.044 -.354 -.022 .187 -.243 .491 .509 .462 .561 .483 .359 .622
Frontal -.181 -.083 -.061 -.348 -.018 .225 -.262 .467 .481 .443 .545 .459 .313 .618
Temporal -.317 -.183 -.166 -.450 -.140 .342 -.278 .434 .454 .404 .523 .419 .282 .596
Mesial temporal -.376 -.092 -.312 -.479 -.325 .413 -.392 .427 .438 .407 .476 .420 .319 .514
Parietal -.219 -.061 -.120 -.351 -.145 .207 -.188 .474 .487 .451 .523 .481 .367 .569
Occipital -.391 -.439 -.101 -.619 -.111 -.012 -.253 .486 .486 .477 .567 .508 .278 .648
Central .005 -.001 .122 -.251 .044 -.019 -.030 .516 .518 .504 .562 .544 .372 .611
Cingulate -.234 .044 -.234 -.282 -.148 .341 -.442 .531 .558 .491 .601 .516 .420 .658
Thalamus .021 .098 .098 -.141 .180 .311 -.309 .844 .866 .804 .806 .845 .855 .765
doi:10.1371/journal.pone.0131486.t001
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Fig 3. Regression plot of IQ (TIQ: total IQ, VIQ: verbal IQ, PIQ: performance IQ; Scaled IQ values) and
SCALED index scores (VCI: verbal comprehension index, POI: perceptual organization index, WMI:
workingmemory index, PSI: processing speed index) against thalamic BPND.
doi:10.1371/journal.pone.0131486.g003
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consequence only benzodiazepine sensitive GABAA receptors are measured. For instance,
occupancy of the δ-containing extrasynaptic GABAA receptors is not recorded. This is the
most significantly under expressed receptor subunit in fragile X mice on the RNA level [28,
29]. Measurement of all receptor subtypes might reveal even larger differences between patients
and controls. An alternative explanation for the decreased BPND values is that the receptor
affinity for flumazenil, rather than the density, is altered in FXS patients. Flumazenil interacts
with the benzodiazepine binding site, which is composed of an α1,2,3 or 5 subunit together with
a βn and γ2 subunit. We previously found decreased expression of the α1,3, β1,2 and γ2 mRNA
without compensatory up regulation of the remaining subunits in the FXS mouse, suggesting
that the amount of benzodiazepine binding site containing subtypes of the receptor are reduced
in the mouse model [28].
All patients were neuropsychologically tested and it is remarkable that the patient showing
the highest total BP value in the range of the controls also has the highest IQ, a score of 69 (S2
Fig). When we correlated the flumazenil BP with the scaled IQ and index scores, we found that
the BP value of the thalamus was positively correlated with the IQ scores and index scores in
the patient but not in the control group. The thalamus has not been previously implicated in
the fragile X syndrome pathology, apart from neuroanatomical studies that demonstrated an
increased volume of this brain structure in women and children (20–22). However, it's impor-
tant to note that the size of our cohort in this pilot study is not sufficient to draw significant sta-
tistical conclusions concerning a possible correlation between GABAA receptor availability and
IQ scores and studies on a much larger cohort of patients are necessary to confirm such a possi-
ble correlation. In this regard, it is important to mention that the sample size required reaching
80% power with a significance level lower than 0.01 is 56 patients. Given the difficulty of
recruiting patients for this study, which includes a full day of neurological and neuropsycholog-
ical testing and a PET scan, we concluded that a study of this size is logistically not feasible
with fragile X patients, and decided to perform this study with a smaller sample size of n = 10.
GABAA receptors are the major inhibitory neurotransmitter receptors in the mammalian
brain implicated in anxiety, depression, epilepsy, insomnia, and learning and memory [8], pro-
cesses disturbed in fragile X syndrome. Diminished expression of the GABAA receptor in frag-
ile X syndrome may thus have functional consequences that relate to the behavioral and
epileptic phenotype associated with fragile X syndrome [30]. Using PET, we were able to vali-
date in vivo a reduction in the amount of the GABAA receptor as previously observed in mice
and fly models. This is the first time that a potential target for treatment of fragile X syndrome
has been visualized directly in the brain of patients.
Currently, FXS patients are prescribed various drugs that are aimed at symptomatic treat-
ment and targeted treatment is lacking. Most recently, increased insights into the pathophysiol-
ogy of FXS have raised hopes for the patient [30–33]. Two receptor systems emerged as the
most promising targets for drug treatment, including the mGluR5 receptor and the GABAA
receptor. Enhanced signalling through mGluR5 is hypothesized to be responsible for cognitive
and behavioral deficits in fragile X patients [34]. Trials dampening mGluR signalling in human
patients, either by acting directly on the receptor or indirectly by stimulating the metabotropic
GABAB receptor, which results in the repression of glutamate release from presynaptic termi-
nals, were reported at least partially effective in the most severely affected patient group in one
study were the patients were treated with AFQ056 [35] and in the group with the highest social
withdrawal in a second study were the patients were treated with STX 209 [36]. Deficits in
GABAA receptor signalling are equally apparent in the disorder [30]. Pharmacological
approaches targeting the GABAA receptor in the FXS mouse model have been successful in
correcting amygdala-based symptoms [14], in preventing epileptic seizures [11] and in correct-
ing multiple behavioural abnormalities [12–14]. Patient trials using ganaxolone, a neurosteroid
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drug targeting the GABAA receptor have been initiated (www.clinicaltrials.govNCT01725152).
In addition to visualizing for the first time GABAA receptor occupancy in brain of FXS
patients, our study also predicts that some patients might respond better than others to treat-
ment with drugs targeting the GABAA receptor, a phenomenon also observed in previous clini-
cal trials targeting the glutamatergic system [35, 36]. Our results indicate that in some patients
the target receptors are more compromised than in others. As such, the GABAA receptor occu-
pancy quantification using [11C]flumazenil may have the potential to serve as a biomarker to
predict the efficacy of treatment with drugs targeting this receptor in FXS.
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